Hematologic Oncology | Specialty

Intensive Chemotherapy Boosts Prognosis in Older Teens With Acute Lymphoblastic Leukemia

March 13th 2011

New data demonstrate that older adolescents with acute lymphoblastic leukemia (ALL) can be cured using risk-adjusted intensive chemotherapy without prophylactic cranial irradiation or routine stem cell transplantation.

The Aggressive Peripheral T-Cell Lymphomas

March 13th 2011

The aggressive peripheral T-cell lymphomas make up less than 10% of all lymphomas diagnosed each year in the United States.

Crisis Averted? Manufacturers Scurry to Meet Demand for Drugs

March 12th 2011

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

Net Guides: Non-Hodgkin Lymphoma

March 10th 2011

Useful Online Resources and Clinical Trials for Non-Hodgkin Lymphoma

Net Guides: Acute Myelogenous Leukemia

March 10th 2011

Useful Online Resources and Clinical Trials for Acute Myelogenous Leukemia

ASH 2010: Large International Study Backs Use of Imatinib in Adults With Ph ALL

March 10th 2011

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia

ASH 2010: A New Scoring System Assesses the Risk of Recurrent Venous Thromboembolism

March 10th 2011

A new scoring system has been developed that is designed to predict the risk of recurrent venous thromboembolism (VTE) in a patient with cancer.

ASH 2010: Ponatinib Inhibits Mutations That Block Treatment Paths for CML, ALL, and AML

March 10th 2011

An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.

ASH 2010: Data Support Escalated BEACOPP as Superior Method of Tumor Control in Early Unfavorable Hodgkin Lymphoma

March 10th 2011

In patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.

Do Breast Implants Increase Cancer Risk?

March 10th 2011

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

March 9th 2011

The novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.

ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma

March 9th 2011

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.

ASH 2010: Intensified R-ACVBP More Effective and More Toxic Than R-CHOP in Diffuse Large B-Cell Lymphoma

March 9th 2011

Intensified immunochemotherapy with R-ACVBP significantly improved event-free survival, progression-free survival, disease-free survival, and overall survival compared with R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL), but at the cost of increased hematologic toxicity.

Evolving Treatment Options for Older Patients with AML

March 9th 2011

About 13,300 new cases of acute myeloid leukemia (AML) are diagnosed yearly, and nearly 9,000 deaths occur in the United States.

ASH 2010: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients

March 9th 2011

Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.

ASH 2010: Brentuximab Vedotin Produces High Response Rate in Relapsed or Refractory Hodgkin Lymphoma

March 9th 2011

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a pivotal phase II study involving younger patients with relapsed or refractory Hodgkin lymphoma.

ASH 2010: Bosutinib Shows Promise as First-line Treatment of Chronic Myelogenous Leukemia

March 9th 2011

Bosutinib (SKI-606) seems poised to join the tyrosine kinase inhibitors (TKIs) imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) as a first-line therapy option for patients with chronic myelogenous leukemia in the chronic phase.

ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients

March 9th 2011

In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).

Dr. Pearlstone on Technological Challenges

March 8th 2011

ASH 2010: Brentuximab Showing Promise as Hodgkin Lymphoma Therapy

March 8th 2011

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a phase II study of younger patients with relapsed or refractory Hodgkin lymphoma (HL) who had no other treatment options